This drug has antiemetic, anti-seizure, analgesic and antitussive properties and has been used to control motion sickness-associated vomiting and chronic coughing associated with bronchitis in dogs. It has also been used to treat repetitive self-directed scratching, biting, or chewing in dogs with atopy.
In humans, it is used to reduce opioid and alcohol dependence.
A metabolite of dextromethorphan, dextrorphan, has been shown to behave pharmacodynamically in a similar manner to dextromethorphan.
Due to its half-life, rapid clearance and poor bioavailability, dextromethorphan has limited potential as a chronically administered therapeutic drug in dogs.
Recommended dose rate in dogs is 0.5 - 2.0 mg/kg given orally every 12 - 24 hours.
- Bolser DC (2009) Central mechanisms II: pharmacology of brainstem pathways. Handb Exp Pharmacol 187:203–217
- Dodman NH et al (2004) The use of dextromethorphan to treat repetitive self-directed scratching, biting, or chewing in dogs with allergic dermatitis. J Vet Pharmacol Ther 27(2):99-104
- Manning BH et al (1996) Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain 67(1):79-88
- Kukanich B & Papich MG (2004) Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. J Vet Pharmacol Ther 27(5):337-341